Preliminary Analysis on the Prognostic Factors of Long-term Myelosuppression in Patients With Ovarian Epithelial Cancer After Initial Treatment

黄翠玉,王同霞,吴章鑫,梁华茂,吴郁,郭红燕

DOI: https://doi.org/10.3969/j.issn.1009-6604.2023.04.001

2023-01-01

Abstract:Objective To analyze the influencing factors of the occurrence of long-term myelosuppression in patients with ovarian epithelial carcinoma after initial treatment. Methods Clinical data of 572 patients with ovarian epithelial cancer who received initial treatment from January 2012 to June 2022 were retrospectively analyzed. Due to long retrospective time, the sample size of the two groups was matched of 1∶3 according to the treatment time. The patients were divided into the long-term myelosuppression group（n=54） and the non-long-term myelosuppression group（n=162） according to whether there was myelosuppression at 3 months after initial treatment. The age, body mass index（BMI）, pathological type, stage, grade, chemotherapy regimen, chemotherapy course, prophylactic use of colony stimulating factors and severe myelosuppression during chemotherapy were compared between the two groups. Results Univariate analysis showed that there were no significant differences in age, BMI, pathological type, treatment style, residual lesion, chemotherapy regimen, chemotherapy course and prophylactic use of colony stimulating factors between the two groups（P＞0.05）. The pathological grade 2-3（OR=6.400, P=0.005）, pathological stage Ⅳ（OR=2.403, P=0.046）, and ≥ 2 times of severe myelosuppression during chemotherapy（OR=2.080, P=0.020） were associated with a higher risk of long-term myelosuppression. Multivariate analysis showed that ≥ 2 times of severe myelosuppression during chemotherapy（OR=1.962, 95% CI: 1.024-3.757, P=0.042） was an independent influencing factor of the occurrence of long-term myelosuppression.Conclusions Occurrence of severe myelosuppression ≥ 2 times during chemotherapy is an independent prognostic factors for long-term myelosuppression in patients with ovarian epithelial cancer after initial treatment. Prophylactic use of colony stimulating factors does not reduce the risk of long-term myelosuppression.